Tiziana Life Sciences Ltd(TLSA)Earnings, Financials & Key RatiosTiziana Life Sciences Ltd (TLSA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q4
the company's rapid erosion of its asset base from $57.9M in 2021Q2 to $11.5M in 2025Q4, combined with a critical liquidity position, suggests substantial risk of further shareholder dilution.
Tiziana Life Sciences Ltd (TLSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Tiziana Life Sciences Ltd (TLSA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $0.22vs $0.09-143.0% | — |
| Q3 2025 | Jul 8, 2025 | $0.10vs $0.07-35.4% | — |
| Q3 2025 | Jun 23, 2025 | $0.13 | — |
| Q2 2025 | May 20, 2025 | $0.06 | — |
Recent stock market news and headlines for Tiziana Life Sciences Ltd (TLSA)
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its investor day, prompting analysts at Bank of America and...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS), with topline data expected in late Q3 or early Q4 2026. The company said results are planned to be presented at the 10th joint ACTRIMS-ECTRIMS meeting in Toronto in October 2026.
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the last patient in its ongoing Phase 2a clinical trial has received their first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Key metrics vs top competitors for Tiziana Life Sciences Ltd (TLSA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.26 | $80.17M | -3.94 | — | — | -924.32% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $7.60 | $216.02M | -3.17 | -51.43% | -173.47% | -36.55% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — |
Tiziana Life Sciences Ltd (TLSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TLSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tiziana Life Sciences Ltd (TLSA) stock FAQ — growth, dividends, profitability & financials explained
Tiziana Life Sciences Ltd (TLSA) reported a net loss of $34.9M for fiscal year 2025.
Tiziana Life Sciences Ltd (TLSA) has a return on equity (ROE) of -924.3%. Negative ROE indicates the company is unprofitable.
Tiziana Life Sciences Ltd (TLSA) had negative free cash flow of $14.1M in fiscal year 2025, likely due to heavy capital investments.
